Lei Zhang1, Wang Ma2, Yuanbao Liu3, Yong Wang1, Xiang Sun3, Ying Hu3, Xiuying Deng3, Peishan Lu3, Fenyang Tang3, Zhiguo Wang4, Minghao Zhou5,6. 1. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. 2. First Affiliated Hospital of Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. 3. Department of Expanded Programme on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, Jiangsu Province, China. 4. Department of Expanded Programme on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, Jiangsu Province, China. 1020389031@qq.com. 5. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu Province, China. zmhjscdc@126.com. 6. Department of Expanded Programme on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, Jiangsu Province, China. zmhjscdc@126.com.
Abstract
BACKGROUND: In recent years, outbreaks of varicella have continued to occur, and the coverage rate of varicella vaccine in Jiangsu Province, China, remains unclear. This study aims to analyse the levels of immune antibody against varicella and obtain a comprehensive understanding of the varicella attenuated live vaccine (VarV) coverage rate in children aged 1-9 years in Jiangsu Province. METHODS: From June to October 2016, a cross-sectional survey was conducted to collect 3631 serum samples from healthy children aged 1-9 years in Jiangsu Province. The immunoglobulin G (IgG) antibody levels of varicella were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: The VarV coverage rate of healthy children was only 43.1% (95% CI: 41.1-44.7%). The seroprevalence after vaccination with a single dose of VarV was only 57.1%, and the overall seropositivity and geometric antibody titre (GMC) were 43.5% and 225.4 mU/ml, respectively. The seropositivity was significantly higher in girls than in boys (χ2 = 18.82, P < 0.001). The difference in seropositivity between the 5-9 age group and 1-4 age group was statistically significant (χ2 = 84.31, P < 0.001). The difference in seropositivity between different regions was statistically significant, with the highest seropositivity in the northern area, 53.7% (χ2 = 35.64, P < 0.001). The seropositivity in the group receiving one dose of VarV was significantly higher than that of the unvaccinated group (χ2 = 205.16, P < 0.001). Linear regression analysis suggested that the GMC of varicella antibodies wanes with the time since vaccination (F = 65.01, P = 0.002). CONCLUSION: The VarV coverage rate of healthy children in Jiangsu Province was low. Sero-conversion rates were also low after one dose of VarV, and the immune effectiveness of a single dose of VarV was limited. To control the spread of varicella, VarV should be included in the routine immunization program, and strengthened immunization measures for the varicella-susceptible population warrant additional consideration.
BACKGROUND: In recent years, outbreaks of varicella have continued to occur, and the coverage rate of varicella vaccine in Jiangsu Province, China, remains unclear. This study aims to analyse the levels of immune antibody against varicella and obtain a comprehensive understanding of the varicella attenuated live vaccine (VarV) coverage rate in children aged 1-9 years in Jiangsu Province. METHODS: From June to October 2016, a cross-sectional survey was conducted to collect 3631 serum samples from healthy children aged 1-9 years in Jiangsu Province. The immunoglobulin G (IgG) antibody levels of varicella were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: The VarV coverage rate of healthy children was only 43.1% (95% CI: 41.1-44.7%). The seroprevalence after vaccination with a single dose of VarV was only 57.1%, and the overall seropositivity and geometric antibody titre (GMC) were 43.5% and 225.4 mU/ml, respectively. The seropositivity was significantly higher in girls than in boys (χ2 = 18.82, P < 0.001). The difference in seropositivity between the 5-9 age group and 1-4 age group was statistically significant (χ2 = 84.31, P < 0.001). The difference in seropositivity between different regions was statistically significant, with the highest seropositivity in the northern area, 53.7% (χ2 = 35.64, P < 0.001). The seropositivity in the group receiving one dose of VarV was significantly higher than that of the unvaccinated group (χ2 = 205.16, P < 0.001). Linear regression analysis suggested that the GMC of varicella antibodies wanes with the time since vaccination (F = 65.01, P = 0.002). CONCLUSION: The VarV coverage rate of healthy children in Jiangsu Province was low. Sero-conversion rates were also low after one dose of VarV, and the immune effectiveness of a single dose of VarV was limited. To control the spread of varicella, VarV should be included in the routine immunization program, and strengthened immunization measures for the varicella-susceptible population warrant additional consideration.
Authors: Ouzama Henry; Jerzy Brzostek; Hanna Czajka; Giedra Leviniene; Olga Reshetko; Roberto Gasparini; Petr Pazdiora; Doina Plesca; Maria Giuseppina Desole; Rimantas Kevalas; Giovanni Gabutti; Michael Povey; Bruce Innis Journal: Vaccine Date: 2017-12-07 Impact factor: 3.641
Authors: Tamar A Smith-Norowitz; Tehila A Saadia; Kevin B Norowitz; Rauno Joks; Helen G Durkin; Stephan Kohlhoff Journal: Infect Dis Ther Date: 2017-12-22
Authors: Hua Zhu; Han Zhao; Rong Ou; Qing Zeng; Ling Hu; Hongfang Qiu; Manoj Sharma; Mengliang Ye Journal: Int J Environ Res Public Health Date: 2020-01-20 Impact factor: 3.390